Supporting equitable access to legal and regulated psychedelic medicine for all Canadians.

ABOUT OUR WORK

Working with partners in government, business, and the community, MAPS Canada is committed to advancing psychedelic medicine by supporting scientific, multidisciplinary research; advocating for drug policy reform; offering public education; and supporting equitable access to legal and regulated psychedelic medicine in Canada. 

LATEST AT MAPS CANADA

June 6th, 2024

MAPS Canada Research Room presents:

Psychedelics for Veterans in Canada: Special Considerations


Thurs, June 6th 8pm EST / 5pm PST

Dr. Ronald Shore, MPA, PhD., is a Research Scientist with Queen’s Health Sciences, an Assistant Professor in the Department of Psychiatry, Queen’s University and a Scientific Advisor to the Canadian Institute for Military and Veteran Health Research. Ron is an Investigator and Lead Therapist at Queen’s in a trial of psilocybin plus motivational enhancement therapy for alcohol use disorder. His PhD is specific to the clinical application of psilocybin. Dr. Shore is also faculty in the Michener Institute’s Foundations of Psychedelic-assisted Therapy educational program and is the founder of Kingston’s Street Health Centre.

click to enlarge

July 17th - 21st, 2024

2024 Canadian Psychedelic Summit

Cortes Island, BC

Join us at the Canadian Psychedelic Summit, happening on Cortes Island, BC, from July 17-21, 2024. This gathering is a connective retreat that will bring together a diverse group of Indigenous, grassroots, and sectoral leaders from across Canada to explore a vision for psychedelics in our nation centered around equity and ethics.

Supported by our Community Partner, MAPS Canada and led by facilitator Kim Haxton, the Summit takes place at Hollyhock, on the traditional and unceded territories of the Klahoose, Tla’amin, and Homalco Nations. Join us to center the embodied knowledge of Indigenous peoples, creating space for (un)learning, storytelling, and connection with ourselves, one another, and the natural world. 

 

Partial and full scholarships are available for individuals from equity-seeking communities.  

 

Spots are limited! Register today! 

click to enlarge

April 24th, 2024

MAPS Canada Presents:

Wisdom From The Psychedelic Underground

Podcast with Rachel Harris

Rachel Harris, PhD, is the author of “Swimming in the Sacred: Wisdom from the Psychedelic Underground” and “Listening to Ayahuasca.” A psychologist who has been in private practice for 40 years, she spent 10 years in an academic research department where she published more than 40 scientific studies in peer-reviewed journals and received a National Institutes of Health New Investigator’s Award. Rachel splits her time between an island in Maine and the San Francisco Bay Area

Visit her online at http://www.swimminginthesacred.com

And consider donating to MAPS Canada at https://mapscanada.org/donate/

March 26th, 2024

MAPS Canada presents:

Navigating MDMA-Assisted Therapy: From Research to Clinical Practice

March 26th, 4pm PST, 5pm CST, 7pm EST

Join Dr. Scott Shannon (MAPS principal investigator on its Phase 3 MDMA Clinical Trial),  and ATMA CEO, Vu Tran to learn more about In-Person MDMA-Assisted Therapy Training, based on MAPS protocols, coming to Calgary in May 2024 as well as ATMA-CENA plans for expanding  clinic infrastructure in Canada.  With priority review in the US by the FDA and the expected priority review in Canada initiated by Lykos, there is an urgency for both training and clinics to be ready for legalization.

The FDA recently granted Lykos Therapeutics (formerly MAPS PBC) a priority review on their New Drug Application (NDA) for MDMA, allowing for a shorter review period of 6 months vs the 10 months conventional review period.  The FDA could grant Lykos MDMA approval for therapy as early as August 2024.  The rescheduling MDMA could be another 3 months from FDA approval but it’s likely MDMA-assisted therapy (MaT) will be available to some individuals before the end of 2024.  Training and clinic infrastructure to provide MDMA-assisted therapy is quickly becoming the priority to focus on to make this treatment accessible in both the US and Canada.

The expectation is that Lykos will take a similar path of requesting a priority review to Health Canada for a New Drug Submission (NDS) upon approval from the FDA.  Although legalization for MaT in Canada will be behind the US, we could likely see Health Canada approval early to mid 2025.

 

Join Reverdi Darda, MAPS Canada Board member, in discussion with Dr. Shannon and Vu Tran as we discuss these exciting and rapidly-unfolding developments in psychedelic assisted therapy in Canada.

*Recording will be available for 30 days after the event for the same email address that was used to register

Learning Objectives 

  1. Learn about the specifics of MDMA-Assisted Therapy Training utilizing the MAPS Protocol
  2. Learn about how clinics prepare for MDMA-Assisted Therapy
  3. Hear practitioners’ perspectives on what the path towards legal MDMA-assisted therapy may look like in Canada
  4. Hear practitioners’ perspectives on how the rollout of MDMA-assisted Therapy may look in Canada

Dr. Scott Shannon, (MAPS principal investigator on its Phase 3 MDMA Clinical Trial)

Scott has been a student of consciousness since his honor’s thesis on that topic at the University of Arizona in the 1970s. Following medical school, MDMA assisted psychotherapy became a facet of his practice before this medicine was scheduled in 1985. He then completed a psychiatry residency at a Columbia program in New York. Scott studied cross-cultural psychiatry and completed a child/adolescent psychiatry fellowship at the University of New Mexico. Scott has published four books on holistic and integrative mental health including the first textbook for this field in 2001. He founded Wholeness Center, the largest integrative mental health center in the US, in 2010 with a group of aligned professionals to create innovation in collaborative mental health care.

Scott is a past president of two national medical organizations. He serves as a site Principal Investigator and therapist for the Phase III trial of MDMA assisted psychotherapy for PTSD and for the Phase IIB trial of LSD for generalized anxiety disorder. He has also published numerous articles about his research on cannabidiol (CBD) in mental health. Scott co-founded the Psychedelic Research and Training Institute (PRATI) to train professionals in ketamine-assisted psychotherapy and deliver clinically relevant studies. Scott helped to initiate the Board of Psychedelic Medicine and Therapies in 2021. He lectures all over the world to professional groups interested in a paradigm shifting perspective about transformative care. 

 

Vu Tran, ATMA CEO

Vu is a student of plant medicine, has his yoga instructor certification and also 20 years of experience as a strategic investor and successful entrepreneur. He believes in pursuing a balanced life of business ambition with life giving work, that which nourishes the human spirit.

 

Vu is a life long entrepreneur and has founded, scaled and exited multiple ventures in a variety of markets including real estate, land development, hospitality, entertainment, retail and cannabis. Whether owned, led or partnered with, he has created a combined enterprise value of over $60M from all his ventures to date. As a result of his own experience and work, Vu is deeply involved with and passionate about what psychedelic medicine can bring to Canadians suffering with mental health issues.

April 12th, 2024

MAPS Canada Research Room presents:

Psychedelic Medicine, Panpsychism, and Theodicy


Thurs, April 4th 8pm EST / 5pm PST

Sharday (she/her) is an Associate Professor in the School of Religion at Queen’s University, Kingston ON, where she researches and teaches on esotericism, occult sciences, and new religious movements. She is interested in working with, and enlivening integrative, non-mechanistic worldviews found within these traditions. Her first book is ‘The Spiritual Significance of Overload Boredom’ (2022; McGill-Queen’s University Press). Her major projects right now are about psychedelic spiritual crises and solutions. With multidisciplinary collaborators, she is synthesizing tools for facilitating and navigating existential distress, recovery and maps for meaning-making. This work begins from a cosmophilic starting point, centring epistemologies of direct gnosis from traditional communities of practice, and integrating academic scientific and humanistic epistemologies. Sharday is involved in a number of academic and other organizations: she is a founding member of the Human Augmentation Research Network, she holds leadership positions at the American Academy of Religion, and she has been Director of Research at the Psychedelic Association of Canada.

MAPS Canada's SAP CoP Committee presents:

The Special Access Program Tip Sheet

Our SAP Tip Sheet is now live! Learn how you can access Psychedelic-Assisted Therapy (PAT) through Health Canada’s SAP program. You can find tips and templates to streamline your application process!

MAPS Canada School of Psychedelics

The MAPS Canada School of Psychedelics provides education to promote safe, legal, and equitable access to psychedelic medicines. The school provides programs for everyone from clinicians and researchers to policymakers and to anyone interested in learning more about psychedelics.

BALANCING SAFTEY AND ACCESS REPORT

Please read our report on Alberta’s Regulations and service standards, and related recommendations.

MAPS Canada is powered by a large and dedicated group of volunteers!